Fosun Pharmaceutical (02196): FXS6837 capsules for the treatment of paroxysmal nocturnal hemoglobinuria started a phase III clinical trial in China1

Zhitongcaijing · 1d ago

Zhitong Finance App News, Fosun Pharmaceutical (02196) announced that recently, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Company”), initiated phase III clinical trials on FXS6837 capsules (original project code: XH-S003, hereinafter referred to as “FXS6837”) for the treatment of paroxysmal nocturnal hemoglobinuria in China.